CD5L

1. Coenzyme Q10 + selenium increases CD5L in humans (active: 4.00 +/− 1.27 mg/L vs. placebo: 3.47 +/− 1.27 mg/L).

   “After 48 months of supplementation, a significantly higher CD5L concentration was found in the active group, compared with the placebo group (active: 4.00 +/− 1.27 mg/L vs. placebo: 3.47 +/− 1.27 mg/L; p = 0.01).”

   Human trial48 monthsn = 359

   Serum CD5L Responds Positively to Selenium and Coenzyme Q₁₀ Supplementation with Relation to Thyroid Hormones, Mortality, and Health-Related Quality-of-Life-A Sub-Analysis of a Double-Blind Randomised Placebo-Controlled Trial in Elderly Low in Selenium

   Antioxidants (Basel, Switzerland)·Mar 20, 2025

2. Coenzyme Q10 + selenium increases CD5L in humans.

   “Selenium and coenzyme Q10 supplementation significantly increased CD5L and fT3 levels, in association with a better health outcome.”

   Human trialelderly population low in selenium48 monthsn = 359

   Serum CD5L Responds Positively to Selenium and Coenzyme Q₁₀ Supplementation with Relation to Thyroid Hormones, Mortality, and Health-Related Quality-of-Life-A Sub-Analysis of a Double-Blind Randomised Placebo-Controlled Trial in Elderly Low in Selenium

   Antioxidants (Basel, Switzerland)·Mar 20, 2025

More on Coenzyme Q10 + selenium

1. CD5L decreases total brain volume in humans.

   “Higher CD5L levels were significantly associated with smaller total brain volumes (TCBV)”

   Humansadjusted for APOE ε4 carrier status and additional cardiovascular risk factorsplasman = 2,100

   Association between inflammatory biomarkers and cognitive aging

   PloS one·Sep 9, 2022

More on Total brain volume

1. CD5L is associated with cardiovascular mortality in humans (2.2-fold increased CV mortality risk).

   “As shown in the Kaplan–Meier plot for the placebo group, a significantly higher CV mortality was found in the 1st quartile of CD5L compared to those in the 4th quartile (Q1: 26 deaths out of 49; 53.1% vs. Q4: 12 deaths out of 45: 26.7%; Chi2: 6.69; p = 0.009).”

   Humansin the placebo group48 months

   Serum CD5L Responds Positively to Selenium and Coenzyme Q₁₀ Supplementation with Relation to Thyroid Hormones, Mortality, and Health-Related Quality-of-Life-A Sub-Analysis of a Double-Blind Randomised Placebo-Controlled Trial in Elderly Low in Selenium

   Antioxidants (Basel, Switzerland)·Mar 20, 2025

2. CD5L is associated with cardiovascular mortality in humans.

   “Low CD5L concentrations at inclusion in the placebo group were associated with increased cardiovascular mortality during 10 years of follow-up”

   Humansplacebo group at inclusion10 yearsn = 180

   Serum CD5L Responds Positively to Selenium and Coenzyme Q₁₀ Supplementation with Relation to Thyroid Hormones, Mortality, and Health-Related Quality-of-Life-A Sub-Analysis of a Double-Blind Randomised Placebo-Controlled Trial in Elderly Low in Selenium

   Antioxidants (Basel, Switzerland)·Mar 20, 2025

1. CD5L is associated with health-related quality of life in humans.

   “However, after 48 months, those with a CD5L concentration below the median value displayed a significantly lower score in Hr-QoL compared with those with a CD5L concentration above the median.”

   Humansin the placebo group after 48 months48 months

   Serum CD5L Responds Positively to Selenium and Coenzyme Q₁₀ Supplementation with Relation to Thyroid Hormones, Mortality, and Health-Related Quality-of-Life-A Sub-Analysis of a Double-Blind Randomised Placebo-Controlled Trial in Elderly Low in Selenium

   Antioxidants (Basel, Switzerland)·Mar 20, 2025

1. CD5L raises the risk of mortality in humans (HR 1.22, 95% CI 1.01-1.48).

   “Higher baseline CD5L concentration was associated with increased risk of CVE (HR, 95% CI, 1.17, 1.0-1.36), and all-cause mortality (1.22, 1.01-1.48)”

   Humanschronic kidney disease4 yearsn = 1,516

   Circulating CD5L is associated with cardiovascular events and all-cause mortality in individuals with chronic kidney disease

   Aging·Oct 10, 2021

1. CD5L raises the risk of cardiovascular events in humans (HR 1.17, 95% CI 1.0-1.36).

   “Higher baseline CD5L concentration was associated with increased risk of CVE (HR, 95% CI, 1.17, 1.0-1.36)”

   Humanschronic kidney disease4 yearsn = 1,516

   Circulating CD5L is associated with cardiovascular events and all-cause mortality in individuals with chronic kidney disease

   Aging·Oct 10, 2021

More on Cardiovascular events